Alembic Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 4 Aug 2026

Company page: Alembic Pharmaceuticals share price, financials & guidance record

Alembic Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue growing 26% YoY to INR 2,150 crores and EBITDA up 21% to INR 348 crores. Growth was broad-based, with US Generics leading at 49% YoY, supported by new launches and Bosutinib exclusivity. The company revised its FY27 growth outlook upwards for both US business and overall, while continuing strategic investments in R&D and the US branded platform, which is currently impacting profitability.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 25.0%, net profit up 89.4% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	1,580	1,406	1,571	1,494	1,796 +14%	1,642 +17%	1,719 +9%	1,868 +25%
Expenses	1,321	1,226	1,400	1,280	1,493	1,371	1,445	1,522
EBITDA	259	180	171	214	303 +17%	272 +51%	274 +60%	346 +62%
Margin	16%	13%	11%	14%	17%	17%	16%	19%
Other income	29	15	13	8	11	-32	1	14
Interest	18	22	24	23	23	22	19	21
Depreciation	70	70	69	73	76	80	82	83
Profit before tax	200	104	92	126	216 +8%	139 +34%	173 +88%	256 +103%
Tax rate	17%	17%	18%	18%	17%	18%	-40%	23%
Net profit	166	86	75	104	179 +8%	114 +33%	243 +224%	197 +89%
EPS	8.43	4.37	3.83	5.27	9.12	5.82	12.37	10.02

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls